Literature DB >> 2811853

Three-dimensional steric molecular modeling of the 5-hydroxytryptamine3 receptor pharmacophore.

A W Schmidt1, S J Peroutka.   

Abstract

A computer-based three-dimensional steric molecular model of the 5-hydroxytryptamine3 (5-HT3) receptor pharmacophore was defined on the basis of radioligand binding data. Analysis of published data led to the identification of 19 different chemical structures that share only a single known pharmacological property, i.e., less than 10 nM affinity for the 5-HT3 receptor. These 19 compounds were then categorized into seven chemical families, which derive from six main steric "core" structures. From the composite analysis of all 19 potent agents, nine steric chemical criteria were derived, which can be used to describe the 5-HT3 receptor pharmacophore. This information was then used to explain the 5-HT3 receptor inactivity of atrophine, a compound that differs structurally from ICS 205-930 in the steric properties of only a single key atom. The steric chemical information was also used to predict the activity of serotonergic compounds that had never been analyzed at 5-HT3 receptor binding sites. Two serotonergic drugs that meet all nine steric criteria were found to be active at the 5-HT3 receptor binding site (i.e., pizotifen, KI = 42 +/- 10 nM, and clozapine, KI = 52 +/- 8 nM). By contrast, two serotonergic agents that do not meet the criteria were found to be inactive at the 5-HT3 receptor binding site (i.e., ipsapirone and pirenperone, KI values greater than 1000 nM). This computer-based steric molecular modeling approach allows for the analysis and identification of 5-HT3 receptor-active agents with minimal dependence upon animals and radioactive compounds.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2811853

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors.

Authors:  P A Pierce; J Y Kim; S J Peroutka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

2.  Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites.

Authors:  M L López-Rodríguez; M J Morcillo; B Benhamú; M L Rosado
Journal:  J Comput Aided Mol Des       Date:  1997-11       Impact factor: 3.686

Review 3.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 4.  The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.

Authors:  D C Ohuoha; T M Hyde; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Toward biophysical probes for the 5-HT3 receptor: structure-activity relationship study of granisetron derivatives.

Authors:  Sanjeev Kumar V Vernekar; Hasan Y Hallaq; Guy Clarkson; Andrew J Thompson; Linda Silvestri; Sarah C R Lummis; Martin Lochner
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

Review 6.  Toward a multiscale modeling framework for understanding serotonergic function.

Authors:  KongFatt Wong-Lin; Da-Hui Wang; Ahmed A Moustafa; Jeremiah Y Cohen; Kae Nakamura
Journal:  J Psychopharmacol       Date:  2017-04-18       Impact factor: 4.153

7.  Design, synthesis, and structure-activity relationships of highly potent 5-HT₃ receptor ligands.

Authors:  Mark H P Verheij; Andrew J Thompson; Jacqueline E van Muijlwijk-Koezen; Sarah C R Lummis; Rob Leurs; Iwan J P de Esch
Journal:  J Med Chem       Date:  2012-10-12       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.